EHA 2021 | Patient selection for BiTEs therapies
Sabina Chiaretti
• 24 Jun 2021
Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, talks on patient selection for bispecific T-cell engagers (BiTEs), in particular highlighting the use of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Dr Chiaretti reports that she believes blinatumomab may be beneficial for patients with Philadelphia chromosome-positive ALL, however further research is required. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
